Owlstone Medical won up to $49.1 million from ARPA‑H to develop over‑the‑counter, at‑home breath tests capable of detecting more than 30 cancers at early (stage I) disease. The funding aims to advance volatile organic‑compound‑based diagnostics toward scalable consumer‑facing screening tools. The program will focus on analytical validation, clinical performance in early‑stage cancers, manufacturing scale‑up, and user workflows needed for a point‑of‑care home product. ARPA‑H framed the award as an effort to democratize early cancer detection by shifting screening out of clinical settings. If successful, the work could alter screening paradigms by enabling frequent, low‑cost surveillance and earlier interventions across multiple tumor types.